Financing transformative health systems towards achievement of the health Sustainable Development Goals: a model for projected resource needs in 67 low-income and middle-income countries

Autor: Karin Stenberg, MSc, Odd Hanssen, MSc, Tessa Tan-Torres Edejer, MSc, Melanie Bertram, PhD, Callum Brindley, BEcom, Andreia Meshreky, MSc, James E Rosen, MA, John Stover, MA, Paul Verboom, MBA, Rachel Sanders, MPP, Agnès Soucat, PhD

Publikováno v: The Lancet Global Health, Vol 5, Iss 9, Pp e875-e887 (2017)

Background: The ambitious development agenda of the Sustainable Development Goals (SDGs) requires substantial investments across several sectors, including for SDG 3 (healthy lives and wellbeing). No estimates of the additional resources needed to st

Externí odkaz: https://doaj.org/article/e181ae140a694be4876cee171187ea41

Developing a multisectoral National Action Plan for Health Security (NAPHS) to implement the International Health Regulations (IHR 2005) in Tanzania

Autor: Rachel B. Eidex, Ibrahima Socé Fall, Neema Rusibamayila, Stella Chungong, Ali Ahmed Yahaya, Paul Verboom, Janneth Mghamba, Muhammad Bakari, Martin Muita, Mohamed Ally, Glenn P M Lolong, S Nikkari, Grace Elizabeth Bai Saguti, Ambrose Talisuna, Guenael Rodier, Richard Banda, Ludy Suryantoro, Karen Sliter, Rajesh Sreedharan, Jubilate Bernard, Sohel Saikat, Maximillian Mapunda

Publikováno v: BMJ Global Health

The Ebola outbreak in West Africa precipitated a renewed momentum to ensure global health security through the expedited and full implementation of the International Health Regulations (IHR) (2005) in all WHO member states. The updated IHR (2005) Mon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46b2841d8a22c7800ead80db22a8df27
http://europepmc.org/articles/PMC5873533

Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits

Autor: Chris J.L.M. Meijer, MT Groot, Michael G. Hanna, Paul Verboom, Jan B. Vermorken, C.A. Uyl-de Groot, Herbert M. Pinedo, Gouke J. Bonsel

Publikováno v: Vaccine, 23(17-18), 2379-2387. Elsevier BV
Uyl-de Groot, C A, Vermorken, J B, Hanna, M G J, Verboom, P, Groot, M T, Bonsel, G J, Meijer, C J L M & Pinedo, H M 2005, ' Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits ', Vaccine, vol. 23, no. 17-18, pp. 2379-2387 . https://doi.org/10.1016/j.vaccine.2005.01.015
Vaccine, 23(17-18), 2379-2387. Elsevier
Vaccine

We have completed a multicenter, randomized controlled phase III clinical trial in Stages II and III colon cancer patients with active specific immunotherapy (ASI) using autologous tumor cells with an immunomodulating adjuvant bacillus Callmette-Guer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb8a951197e4af0efcad44b5c1483dd
https://hdl.handle.net/1871/26473

Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer:A Dutch cooperative randomized study

Autor: Otto S. Hoekstra, Carin A. Uyl-de Groot, Harm van Tinteren, Jan Pruim, Paul Verboom, Harry J.M. Groen, Maarten Boers, Marinus A. Paul, Pieter E. Postmus, Emile F.I. Comans, Gerrit J.J. Teule, Alle Welling, Henk Kramer, Egbert F. Smit, Gerarda J.M. Herder

Publikováno v: Herder, G J M, Kramer, H, Hoekstra, O S, Smit, E F, Pruim, J, Van Tinteren, H, Comans, E F, Verboom, P, Uyl-de Groot, C A, Welling, A, Paul, M A, Boers, M, Postmus, P E, Teule, G J & Groen, H J M 2006, ' Traditional versus up-front [ 18 F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer : A Dutch cooperative randomized study ', Journal of Clinical Oncology, vol. 24, no. 12, pp. 1800-1806 . https://doi.org/10.1200/JCO.2005.02.4695
Journal of Clinical Oncology, 24(12), 1800-1806. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 24(12), 1800-1806. American Society of Clinical Oncology

Purpose We investigated whether application of positron emission tomography (PET) immediately after first presentation might simplify staging while maintaining accuracy, as compared with traditional strategy in routine clinical setting. Methods At fi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca267cf32333772d6ac66df17fc52a44
https://research.vumc.nl/en/publications/d554ac6e-288a-49d0-80c7-8b175073b39d

Cost-effectiveness of FDG-PET in staging non-small cell lung cancer:The PLUS study

Autor: Pieter E. Postmus, Johan C. van Mourik, Harm van Tinteren, Maarten Boers, Jan H.A.M. Van Den Bergh, Paul Verboom, Carin A. Uyl-de Groot, Ad J.M. Schreurs, Roland A. L. M. Stallaert, Gerrit J.J. Teule, Piet C.M. Van Velthoven, Fred W. Diepenhorst, Egbert F. Smit, E. W. M. Grijseels, Otto S. Hoekstra, Emile F.I. Comans

Publikováno v: Verboom, P, Van Tinteren, H, Hoekstra, O S, Smit, E F, Van den Bergh, J H A M, Schreurs, A J M, Stallaert, R A L M, Van Velthoven, P C M, Comans, E F I, Diepenhorst, F W, Van Mourik, J C, Postmus, P E, Boers, M, Grijseels, E W M, Teule, G J J & Uyl-de Groot, C A 2003, ' Cost-effectiveness of FDG-PET in staging non-small cell lung cancer : The PLUS study ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 30, no. 11, pp. 1444-1449 . https://doi.org/10.1007/s00259-003-1199-9
European Journal of Nuclear Medicine and Molecular Imaging, 30(11), 1444-1449. Springer Verlag

Currently, up to 50% of the operations in early-stage non-small cell lung cancer (NSCLC) are futile owing to the presence of locally advanced tumour or distant metastases. More accurate pre-operative staging is required in order to reduce the number

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2899f775f492a7875d1e103fd5c153d
https://research.vumc.nl/en/publications/842b8e8a-bfe3-473a-8033-915154bfd529